Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.
aTen Therapeutics is a biotechnology company focused on developing innovative therapeutic antibodies aimed at treating major diseases, particularly cancer. The company's unique approaches target a fundamental control pathway associated with various diseases, enabling the development of treatments that can significantly improve patient outcomes. aTen Therapeutics' antibodies are designed to inhibit cancer cell growth, invasion, and metastasis across multiple tumor models. By combining these antibodies with anti-cancer agents, the company seeks to enhance the efficacy of cancer treatments and provide healthcare professionals with effective tools to improve the lives of cancer patients while protecting against the progression of metastases. The management team possesses extensive experience in the biopharmaceutical industry, emphasizing the company's commitment to advancing medical science and patient care.
Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. The company offers a range of products, including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate's project, "Liver on chip," focuses on liver toxicity testing and incorporates advanced techniques in cellular reprogramming and organ-on-chip technology. The company also provides services such as cell reprogramming, differentiation, and application development. Its clientele includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions, enabling researchers to overcome challenges associated with traditional mammalian cell lines in drug discovery.
Awakn Life Sciences Corp is a clinical-stage biotechnology company intended to develop therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. The Company focuses on Alcohol Use Disorder (AUD), a condition affecting people in the US and key international markets and many people globally for which the current standard of care is inadequate, enabling it to provide breakthrough therapeutics to addiction sufferers in desperate need.
Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.
Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industry professionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease.
STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.
CONNECT Care gives patients the confidence to manage their medications.
Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.
Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.
CONNECT Care gives patients the confidence to manage their medications.
Rinri Therapeutics is a provider of private biotechnology services intended to develop advanced regenerative stem cell-based therapies for the treatment of hearing loss. The company's stem cell technology replaces damaged or dead sensory cells of the inner ear, enabling doctors to restore hearing of patients.
Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of innovative stabilization technology solutions for pharmaceutical and biotech firms. The company partners with these organizations to enhance the commercial value and utility of proteins used in various applications, including vaccines, therapeutic proteins, and treatments for complex diseases. Arecor focuses on developing products for areas such as diabetes, oncology, immunology, and infectious diseases, working to reformulate existing therapies to improve their efficacy and ease of use. Its innovative formulation technology enables high concentrations of antibodies for at-home self-administration and stable liquid formulations for biological therapies. Arecor also addresses challenges related to protein degradation and stability, particularly in the formulation of growth hormones and vaccines. Founded in 2006, Arecor operates primarily in the UK and has a global reach, collaborating with leading pharmaceutical and biotech companies to deliver enhanced therapeutic solutions.
Camallergy Limited, founded in 2015 and based in Cambridge, United Kingdom, specializes in the development and manufacture of oral immunotherapy drugs targeting food allergies, particularly peanut allergies. The company's innovative treatments aim to provide a patient-centric solution that offers rapid protection, allowing individuals to manage their allergies effectively within a few weeks of therapy. By focusing on the needs of those affected by food allergies, Camallergy seeks to enhance the quality of life for patients, enabling them to live without the constant fear associated with allergic reactions.
CN Bio Innovations Ltd, based in Cambridge, United Kingdom, specializes in developing Organ-on-Chip devices aimed at enhancing preclinical drug testing for pharmaceutical and biotechnology companies. The company creates microphysiological systems and consumables that enable consumer goods and chemical firms to assess the toxicity and safety of novel compounds using in vitro studies across various biological processes, including oncology, infectious diseases, metabolism, and inflammation. Formerly known as Zyoxel Ltd, CN Bio is recognized for its proprietary LiverChip® platform, which features a full viral lifecycle model of hepatitis B, called Quantum-B®. This model is utilized in drug discovery and research partnerships with leading industry players. Collaborating with academic experts in bio-engineering and supported by grants from organizations such as the United States Defence Advanced Research Projects Agency and the UK Technology Strategy Board, CN Bio is committed to advancing next-generation organ-on-chip technologies to facilitate the development of innovative therapies that could improve global health outcomes.
Ignite is the UK’s leading provider of technology-driven Patient Recruitment and Real-World Evidence solutions.
Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel. This diverts the blood away from the aneurysm, allowing it to heal.
Lumino is focused on enhancing mental health outcomes through the development of digital therapeutic programs. These programs specifically address various mental health concerns and incorporate techniques such as cognitive behavioral therapy (CBT) to help individuals manage their symptoms effectively. Supported by Innovate UK and the Oxford Academic Health Science Network, Lumino aims to leverage digital technology to deliver scalable mental health services, ultimately promoting healthier and happier lives for users.
Ablatus Therapeutics Limited is a medical device company based in Norwich, United Kingdom, established in 2015. The company specializes in developing innovative tissue ablation technology aimed at treating challenging and often inoperable solid cancer tumors. Its proprietary Bimodal Electric Tissue Ablation technology utilizes radiofrequency energy delivered through a specialized probe to create localized heating that destroys targeted tissues. This approach provides healthcare professionals with advanced clinical options for treating cancer, ultimately improving patient outcomes.
Reflection Therapeutics is developing cell therapy technology against neuroinflammation across the board.
Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing innovative therapeutic solutions that combine established medications with proprietary digital therapeutics. By digitizing and capturing data throughout the entire care continuum, Closed Loop Medicine seeks to create dynamic, personalized treatment regimens tailored to individual patient needs. Their pipeline includes integrated approaches that address significant health challenges such as sleep disorders, hypertension, chronic pain, and diabetes. Through real-time feedback and advanced care pathways, Closed Loop Medicine aims to enhance patient outcomes and improve the overall efficiency of healthcare delivery.
Albus Health is a medical device company that develops a passive and non-contact, nocturnal symptom monitoring device. The company develops Albus Home RD, a completely passive and non-contact home monitoring device that enables a high quantity and quality of data from remote monitoring in research and clinical care.
Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.
In modern healthcare, not only must we focus on prolonging a person's life, but also on maintaining the quality of that life. Functional health information is a powerful tool enabling clinicians to maintain patient quality of life, but it is let down by imperfect assessment tools that are subjective, have poor repeatability and are insensitive to incremental change. Vitrue is a huge leap in functional assessment accuracy and efficiency. Our system will enable occupational and physical therapists to treat more patients, more effectively by providing them with far more advanced and modern assessment tools.
Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing an innovative technology for assessing seizure susceptibility, known as BioEP. The company focuses on diagnosing and prognosing neurological conditions, particularly epilepsy. Its platform utilizes a patented method to calculate a seizure risk score based on routine electroencephalogram (EEG) recordings. This approach aims to enhance early diagnosis and prognosis of epilepsy, thereby enabling healthcare professionals to improve patient quality of life through more informed clinical decisions.
Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing an innovative technology for assessing seizure susceptibility, known as BioEP. The company focuses on diagnosing and prognosing neurological conditions, particularly epilepsy. Its platform utilizes a patented method to calculate a seizure risk score based on routine electroencephalogram (EEG) recordings. This approach aims to enhance early diagnosis and prognosis of epilepsy, thereby enabling healthcare professionals to improve patient quality of life through more informed clinical decisions.
The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.
ExplantLab is an independent research organization located in Newcastle upon Tyne, United Kingdom. The company focuses on exploring the connections between patient genetics and the design, manufacture, and performance of medical devices. By integrating genetic insights into its research, ExplantLab aims to enhance the effectiveness and safety of medical devices, ultimately improving the quality of life for patients.
Lunac Therapeutics
Grant in 2019
Lunac Therapeutics is a UK-based drug discovery company.
Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing innovative, user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions, particularly in the fields of infections and oncology. Its flagship product, True Point-of-Care, serves as a clinical diagnostic tool that empowers users to make informed treatment decisions in a decentralized healthcare environment. By employing advanced molecular methods, including polymerase chain reaction (PCR) technology, Sense Biodetection's equipment allows clinics and medical professionals to detect infections promptly and effectively, facilitating immediate treatment options.
high expertise in the designing and testing of self-assembling peptides providing different benefits when culturing adherent cells in vitro.
BrainWaveBank Limited is a brain health research company focused on developing innovative solutions to track and improve cognitive health, particularly in the context of dementia. Founded in 2015 and based in Belfast, United Kingdom, the company has created a unique wearable electroencephalography (EEG) device that allows users to non-invasively measure their brain activity. This device works in conjunction with mobile games designed to challenge cognitive skills, enabling individuals to monitor their cognitive health daily from the comfort of their homes. By securely collecting and analyzing data from a large user base, BrainWaveBank aims to build comprehensive neurocognitive profiles that can advance the understanding of brain health and inform the development of future treatments for neurological disorders. The company's approach emphasizes scalability and accessibility, making it a valuable tool for both consumers and clinical professionals.
Ixaka is a regenerative medicine company focused on developing advanced cell-based therapeutics aimed at treating serious diseases that lack effective existing therapies. The company is actively conducting clinical trials for its cellular therapies, with the goal of obtaining marketing authorization in Europe, the United States, and other global markets. Ixaka's approach is grounded in a deep understanding of the fundamental science behind cell therapies. Collaborating with the Andalusian Health Authority and the Andalusian Initiative of Advanced Therapies, Ixaka is working to expand its portfolio of cell therapies to address additional indications with significant unmet medical needs.
Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing innovative therapeutic solutions that combine established medications with proprietary digital therapeutics. By digitizing and capturing data throughout the entire care continuum, Closed Loop Medicine seeks to create dynamic, personalized treatment regimens tailored to individual patient needs. Their pipeline includes integrated approaches that address significant health challenges such as sleep disorders, hypertension, chronic pain, and diabetes. Through real-time feedback and advanced care pathways, Closed Loop Medicine aims to enhance patient outcomes and improve the overall efficiency of healthcare delivery.
Albus Health is a medical device company that develops a passive and non-contact, nocturnal symptom monitoring device. The company develops Albus Home RD, a completely passive and non-contact home monitoring device that enables a high quantity and quality of data from remote monitoring in research and clinical care.
Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.
The Cell and Gene Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. Supported by Innovate UK, their mission is to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early stage research into commercially viable and investable therapies. They are based on the 12th floor of Guy’s Hospital in central London, with over 120 cell and gene therapy experts, state-of-the art development and viral vector laboratories. They are also building a £55m large-scale GMP manufacturing centre to help bring cell and gene therapies to market in the UK and internationally.
Our mission is to transform how decisions are made about our health. Decisions informed by patient outcomes, and shared by patient and clinician. Shared decisions, digital consent, better outcomes. Our digital consent platform uses data to inform and design to simplify complexity. Secure, auditable, and a great experience for all our users.
Nanna Therapeutics is a drug discovery company addressing age-related diseases for which others are failing to provide effective treatments. These include mitochondrial, neurodegenerative, cardiovascular or metabolic, joint or tissue disease as well as cancer. Nanna Therapeutics are targeting fundamental cellular processes to create drugs to treat age-related diseases and improve longevity. Such drugs include those to combat debilitating neurodegenerative, inflammatory, cardiovascular and metabolic diseases as well as many cancers. With a strong focus on mitochondria, the energy source in every cell, we can target the fundamental causes of many age-related diseases. Through this approach we can also address debilitating, life-limiting mitochondrial diseases for which there are currently few effective therapies. Nanna Therapeutics has developed a tightly integrated set of proprietary technologies that radically disrupt current methods of creating new medicines. This Totally Integrated Medicines Engine (TIME) has been devised to answer the needs of drug discovery and development scientists utilising the best in 21st century technologies of microfluidics, nanofabrication and artificial intelligence.
In modern healthcare, not only must we focus on prolonging a person's life, but also on maintaining the quality of that life. Functional health information is a powerful tool enabling clinicians to maintain patient quality of life, but it is let down by imperfect assessment tools that are subjective, have poor repeatability and are insensitive to incremental change. Vitrue is a huge leap in functional assessment accuracy and efficiency. Our system will enable occupational and physical therapists to treat more patients, more effectively by providing them with far more advanced and modern assessment tools.
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing exosome-based therapeutics for the treatment of severe diseases. Founded in 2016, the company leverages its proprietary technology to harness and engineer extracellular vesicles, known as exosomes, for the targeted delivery of nucleic acids and proteins. This innovative approach aims to enhance drug delivery to challenging areas, such as the brain and central nervous system, where conventional therapies often fall short. Evox’s mission is to improve human health by creating novel therapeutics that address significant medical needs, particularly for conditions with limited treatment options. The company has built a comprehensive intellectual property portfolio and is backed by prominent life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based drug delivery.
A UK pharmaceutical development company, AKL Research & Development Ltd (AKLRD) is committed to transforming patient’s lives through innovative solutions that meet unmet needs.AKLRD is developing novel therapeutics for inflammatory diseases with a high unmet need, including osteoarthritis, Alzheimer’s, rheumatoid arthritis & scleroderma, a rare connective tissue disease.
It is our mission to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life. Dxcover are an award-winning team, dedicated to developing liquid biopsies for early detection of cancer and other diseases. A University of Strathclyde spinout in 2019 under the name ClinSpec Diagnostics, and rebranded as Dxcover Limited in 2021. To date, Dxcover have secured £5.1m of funding, and have successfully completed two ground-breaking clinical studies on detection of brain cancer and are currently developing our platform for the detection of commonly occurring cancers.
Mendelian is a company focused on accelerating the diagnosis of rare genetic diseases. By utilizing an intelligent agent, Mendelian analyzes patients' clinical features to identify the genes responsible for rare conditions. Physicians input phenotypic details, and the platform generates outputs that indicate potential causative genes and mutations. This innovative approach enhances the investigation of undiagnosed cases, allowing for earlier detection and treatment of rare diseases through machine learning and knowledge reasoning.
MediSieve Ltd. is a London-based medical device company that specializes in developing Magnetic Blood Filtration (MBF) technology for the treatment of blood-borne diseases. The company’s innovative device employs a magnetic filter to remove infected blood cells, making it applicable for conditions such as malaria, leukemia, and sepsis. MediSieve’s system operates by circulating a patient’s blood through an external loop, where targeted magnetic particles bind to specific disease-related targets. The blood is then filtered through a magnetic device that captures these particles and their attached targets, allowing the remainder of the blood to return to the patient without contamination. Founded in 2014 and located at the Imperial Incubator in White City, London, MediSieve has dedicated facilities for product development and validation, including capabilities for various blood testing methods.
PredictImmune Ltd is a company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Its primary product, PredictSURE IBD, is designed to guide treatment options for patients with Inflammatory Bowel Disease, including Crohn's disease and ulcerative colitis. This innovative test utilizes a small blood sample to accurately identify patients at the time of diagnosis who are at risk for severe, relapsing disease. By providing essential information regarding long-term clinical prognosis, the test supports healthcare professionals in determining personalized treatment plans, particularly the timely use of biologics therapy. PredictImmune's approach is recognized as beneficial by physicians, patients, and payors, as it enhances the management of Inflammatory Bowel Disease and improves patient outcomes.
Vitaccess is a multi award-winning digital-health and strategic consultancy, founded in 2017. Though based in Oxford, UK, their reach is truly global. They offer a world-class real-world evidence (RWE) data portfolio and data science research via MyRealWorld™, their state-of-the-art digital platform, and experience-based Market Access and Health Economics and Outcomes Research (HEOR) solutions. Their heritage in HEOR and Market Access makes us a trusted partner to the pharmaceutical industry. They understand the importance of scientific rigor in RWE studies, as well as the complexities of information governance - including GDPR and HIPAA. Industry standards have been applied to the creation of their pioneering and flexible digital platform, MyRealWorld™, through which they capture RWE in real-time, to be transmitted in aggregated, anonymized form to customizable and interactive research dashboards.
Roslin Cells is the parent company of Roslin Cell Therapies. Based in Edinburgh, UK Roslin Cell Therapies has a wealth of expertise, capabilities and industry recognition in process translation to GMP, development, optimization, scale up and the GMP manufacture of Cell Therapy and Advanced Therapy Medicinal Products (ATMPs).
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the delivery of nucleic acid therapeutics, particularly antisense oligonucleotides. Established in 2018, PepGen aims to enhance the clinical efficacy of these therapeutics through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative technology employs engineered peptides designed for optimized tissue penetration, cellular uptake, and nuclear delivery, enabling effective transport of oligonucleotides to various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. By leveraging its drug delivery capabilities, PepGen seeks to transform the treatment landscape for severe neuromuscular and neurological diseases.
RoslinCT is a prominent UK-based contract development and manufacturing organization specializing in cell therapy. The company offers a range of services tailored for organizations developing cell-based therapeutic products, including cell and gene therapy development, tissue procurement, and cryopreservation studies. Additionally, RoslinCT conducts pre-clinical studies and analytical development, ensuring that clients can deliver compliant, sustainable, and affordable therapies. Through its expertise, RoslinCT supports the advancement of innovative treatments in the field of regenerative medicine.
Medherant Limited is a clinical-stage company based in Coventry, United Kingdom, focused on developing innovative treatments for pain and central nervous system diseases through advanced transdermal drug delivery technology. Founded in 2014 by Professor David Haddleton in collaboration with the University of Warwick, Medherant aims to address the limitations of existing patch technologies, which often struggle with drug loading capabilities and are unsuitable for many pharmaceutical products. The company's flagship product, the TEPI Patch, utilizes a novel adhesive that enhances drug delivery by allowing for higher concentrations and faster release rates, while mitigating the issues associated with oral medications, such as gastrointestinal toxicity and low bioavailability.
Ieso Digital Health Ltd. specializes in providing online evidence-based cognitive behavioral therapy (CBT) to individuals facing various mental health challenges, including anxiety and depression. The company's unique online service facilitates real-time communication between accredited therapists and patients through a secure virtual environment, where sessions are conducted via text. This approach not only mirrors traditional face-to-face interactions but also offers greater convenience for users. Ieso began its operations in the UK in 2000 and has since expanded into the US market, collaborating with Medicaid and commercial health plans to enhance access to mental health services. The company’s therapy model has demonstrated effectiveness, requiring fewer sessions to achieve recovery and showing improved outcomes compared to conventional therapy methods. Ieso serves a diverse clientele, including health providers, private individuals, and businesses, and is recognized for its rapid growth in the digital health sector.
STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.
Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing an innovative technology for assessing seizure susceptibility, known as BioEP. The company focuses on diagnosing and prognosing neurological conditions, particularly epilepsy. Its platform utilizes a patented method to calculate a seizure risk score based on routine electroencephalogram (EEG) recordings. This approach aims to enhance early diagnosis and prognosis of epilepsy, thereby enabling healthcare professionals to improve patient quality of life through more informed clinical decisions.
Metrion Biosciences Ltd is a contract research organization specializing in preclinical drug discovery services. Founded in 2015 and based in Cambridge, United Kingdom, the company offers a comprehensive range of services that include ion channel screening, cardiac safety profiling, and neuroscience assays. Metrion provides flexible business models tailored to the needs of its clients, which encompass both fee-for-service and collaborative options. The company is equipped with advanced electrophysiology screening capabilities to support medicinal chemistry optimization programs and integrated drug discovery efforts, ensuring high-quality and compliant preclinical testing.
Elasmogen Ltd, a biopharmaceutical company, discovers and develops sight-saving therapies for inflammatory eye diseases. The company develops soloMER that are small (11 kDa) and stable proteins that have squeezed a fourth binding loop into their single domain format and are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape. Its pipeline includes ELN/21 and ELN/22, which are auto-immune mediated anti-inflammatory programs; soloMER-drug-conjugates; and NDure, a soloMER (humanized clinical candidate) available for extending the plasma half-life of fused partner molecules, such as scFv, peptides, growth factors, single domains, etc. Elasmogen Ltd has strategic partnerships with Almac Discovery Ltd and Merck Inc. The company was founded in 2014 and is based in Aberdeen, United Kingdom.
Almac Group is a prominent contract development and manufacturing organization based in Craigavon, United Kingdom, specializing in a comprehensive array of services for the pharmaceutical and biotech sectors. With over 40 years of organic growth, the company employs more than 4,500 skilled professionals and operates facilities in the UK, Ireland, the United States, and Asia. Almac Group's offerings encompass research and development, biomarker discovery and development, active pharmaceutical ingredient (API) manufacture, formulation development, clinical trial supply, and companion diagnostic development. The group also includes Almac Diagnostics, which focuses on biomarker discovery and validation, providing services such as bioinformatics solutions and genomic analyses. Additionally, Almac Discovery is dedicated to oncology, concentrating on innovative cancer treatment approaches during the discovery and preclinical stages. Through continuous investment in state-of-the-art technology and services, Almac Group supports clients throughout the entire biopharmaceutical product lifecycle, from preclinical development to commercialization.
Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of innovative stabilization technology solutions for pharmaceutical and biotech firms. The company partners with these organizations to enhance the commercial value and utility of proteins used in various applications, including vaccines, therapeutic proteins, and treatments for complex diseases. Arecor focuses on developing products for areas such as diabetes, oncology, immunology, and infectious diseases, working to reformulate existing therapies to improve their efficacy and ease of use. Its innovative formulation technology enables high concentrations of antibodies for at-home self-administration and stable liquid formulations for biological therapies. Arecor also addresses challenges related to protein degradation and stability, particularly in the formulation of growth hormones and vaccines. Founded in 2006, Arecor operates primarily in the UK and has a global reach, collaborating with leading pharmaceutical and biotech companies to deliver enhanced therapeutic solutions.
Emergex Vaccines Holding Ltd is a biotechnology company engaged in the research and development of vaccines for viral and bacterial infectious diseases. Founded in 2016 and based in Abingdon, United Kingdom, Emergex focuses on creating affordable and effective vaccines tailored for low-resource environments that are significantly impacted by pandemics. The company’s vaccine technology targets diseases such as dengue, influenza, zika, hepatitis B, and francisella tularensis. Emergex aims to establish a clinical-grade international vaccine repository that will serve as a first line of defense against both existing and newly emerging infectious disease outbreaks.
Glialign specializes in regenerative technologies aimed at enhancing peripheral nerve repair. The company is developing a novel cell therapy that serves as a living nerve growth guide, designed to replace traditional nerve grafts, which often require harvesting nerves from other body parts. Current treatments for peripheral nerve injuries are only effective in less than half of the cases, highlighting the need for more reliable solutions. Glialign's approach provides an off-the-shelf alternative, enabling healthcare providers to facilitate nerve regeneration and improve functional recovery for patients suffering from nerve injuries.
Sentinel Oncology Limited, a drug discovery company, develops and commercializes therapeutics to treat cancer. The company develops small molecule approaches to target the microenvironment of solid tumors. Its R&D programs pipeline includes Checkpoint Kinase 1, a protein kinase that activates in response to DNA damage and DNA replication stress; and an approach to treat metastatic breast cancer by developing a drug that inhibits S6K1 and offers treatment options for patients. The company was founded in 2005 and is based in Cambridge, United Kingdom.
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
PulmonIR is focused on the research and development of innovative medical devices aimed at detecting and monitoring lung diseases, particularly chronic obstructive pulmonary disease (COPD) and lung cancer. The company's technology is designed to assist healthcare professionals in diagnosing COPD patients more efficiently, allowing for quicker and safer treatment options for those suffering from these conditions. By streamlining the testing process, PulmonIR aims to improve patient outcomes and enhance the overall management of lung diseases.
Metrion Biosciences Ltd is a contract research organization specializing in preclinical drug discovery services. Founded in 2015 and based in Cambridge, United Kingdom, the company offers a comprehensive range of services that include ion channel screening, cardiac safety profiling, and neuroscience assays. Metrion provides flexible business models tailored to the needs of its clients, which encompass both fee-for-service and collaborative options. The company is equipped with advanced electrophysiology screening capabilities to support medicinal chemistry optimization programs and integrated drug discovery efforts, ensuring high-quality and compliant preclinical testing.
Stratified Medicine Scotland Innovation Centre is based in the University of Glasgow’s Clinical Innovation Zone at the Queen Elizabeth University Hospital (QEUH) campus in Glasgow.SMS-IC is a unique consortium of partners, comprising NHS Scotland, four Scottish Universities(Glasgow, Edinburgh, Dundee and Aberdeen) and industrial partners across informatics and genomics (Aridhia Ltd and ThermoFisher Ltd).
Ixaka is a regenerative medicine company focused on developing advanced cell-based therapeutics aimed at treating serious diseases that lack effective existing therapies. The company is actively conducting clinical trials for its cellular therapies, with the goal of obtaining marketing authorization in Europe, the United States, and other global markets. Ixaka's approach is grounded in a deep understanding of the fundamental science behind cell therapies. Collaborating with the Andalusian Health Authority and the Andalusian Initiative of Advanced Therapies, Ixaka is working to expand its portfolio of cell therapies to address additional indications with significant unmet medical needs.
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture. Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient’s cells. This can be either in vivo or ex vivo, the latter encompassing the field of cell therapy whereby genetically modified cells are put back into the body. Their pipeline of seven gene and cell therapy therapy products addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular and central nervous system disorders. Their product candidates have the potential to transform treatment landscapes. Their strategy is to develop their product candidates to their next value inflection points whilst continuing to build OXB Solutions into a valuable revenue-generating manufacturing and development services business.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Spoonful of sugar Ltd. provides evidence-based adherence solutions to healthcare providers. Spoonful of Sugar (SoS) are medicines-related behaviour consultants and solution providers. SoS delivers intelligent medicines engagement programmes and evidence-based adherence solutions on behalf of the pharmaceutical industry and healthcare providers. Our programmes are designed to optimise access and adherence to medication as well as increasing stakeholder concordance and improving health outcomes.
MIOTIFY Ltd. develops software and online toolkit to boost the quality of digital health applications. The company's system allows both developers and non-IT staff to create applications within a guided framework to help them build in quality from the start and auto-generate evidence to include in a submission for regulatory approval. MIOTIFY Ltd. provides new data to enable medics to monitor patients remotely and gather insights to inform their treatment. MIOTIFY Ltd. was incorporated in 2015 and is based in Windsor, United Kingdom.
Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal.
We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas.
This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide.
Having achieved proof of concept in humans, Renephra is raising £400k to conduct device development study and design feasability.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
Albus Health is a medical device company that develops a passive and non-contact, nocturnal symptom monitoring device. The company develops Albus Home RD, a completely passive and non-contact home monitoring device that enables a high quantity and quality of data from remote monitoring in research and clinical care.
Tusk Therapeutics Ltd develops therapeutic antibodies for the treatment of cancer. The company develops immuno-oncology drugs that work for the depletion of regulatory T-cells (Tregs). The company's products include CD25, a Treg depleting agent and CD38, an immune checkpoint which inhibits immunosuppressive cells. The company was founded in 2014 and is based in Stevenage, United Kingdom. As of September 28, 2018, Tusk Therapeutics Ltd operates as a subsidiary of F. Hoffmann-La Roche Ltd.
CN Bio Innovations Ltd, based in Cambridge, United Kingdom, specializes in developing Organ-on-Chip devices aimed at enhancing preclinical drug testing for pharmaceutical and biotechnology companies. The company creates microphysiological systems and consumables that enable consumer goods and chemical firms to assess the toxicity and safety of novel compounds using in vitro studies across various biological processes, including oncology, infectious diseases, metabolism, and inflammation. Formerly known as Zyoxel Ltd, CN Bio is recognized for its proprietary LiverChip® platform, which features a full viral lifecycle model of hepatitis B, called Quantum-B®. This model is utilized in drug discovery and research partnerships with leading industry players. Collaborating with academic experts in bio-engineering and supported by grants from organizations such as the United States Defence Advanced Research Projects Agency and the UK Technology Strategy Board, CN Bio is committed to advancing next-generation organ-on-chip technologies to facilitate the development of innovative therapies that could improve global health outcomes.
Xerion Healthcare Limited is a UK-based company focused on developing and commercializing nanoparticle treatments to enhance the effectiveness of cancer therapies, specifically targeting head, neck, and pancreatic tumors. Founded in 2015, the company utilizes titanium dioxide nanoparticles, a non-toxic semiconductor material, which are injected into tumors prior to standard radiotherapy. This innovative approach amplifies the dose of free radicals produced by X-rays, thereby improving the treatment's efficacy while minimizing potential side effects. By integrating this nanomedicine technology into conventional radiotherapy, Xerion Healthcare aims to provide more effective solutions for patients with challenging cancer types.
Centauri Therapeutics is a UK-based biotechnology company dedicated to discovering and developing innovative molecules aimed at combating life-threatening diseases. The company utilizes its proprietary Alphamer technology, which involves chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the immune response against infections. Each Alphamer consists of two components: one binds to a cell-surface target on the pathogen, while the other presents specific epitopes that engage circulating antibodies. This approach has demonstrated the ability to trigger an immediate antibacterial immune response, effectively clearing infections. Centauri Therapeutics' flexible Chemistry Platform allows for the synthesis of these bifunctional molecules, which are applicable in treating various infectious diseases. Additionally, the company has formed a joint venture, Avvinity Therapeutics, with Horizon Discovery to advance immuno-oncology initiatives, combining Centauri's expertise in Alphamer technology with Horizon's capabilities in gene editing and oncology. Through collaborations in aptamer selection, drug discovery, chemistry, and immunology, Centauri Therapeutics aims to enhance its impact in the field of immunotherapy.
Activirosomes specializes in the development of innovative vaccines and virotherapies aimed at treating viral infections. Utilizing a unique active virosome technology, the company creates multivalent vaccines that target various diseases, including cancer, avian viruses, and Zika virus. Activirosomes focuses on ensuring that its products are not only effective but also safe and affordable, thereby addressing critical healthcare needs in the field of infectious diseases and oncology.
Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.
Sentinel Oncology Limited, a drug discovery company, develops and commercializes therapeutics to treat cancer. The company develops small molecule approaches to target the microenvironment of solid tumors. Its R&D programs pipeline includes Checkpoint Kinase 1, a protein kinase that activates in response to DNA damage and DNA replication stress; and an approach to treat metastatic breast cancer by developing a drug that inhibits S6K1 and offers treatment options for patients. The company was founded in 2005 and is based in Cambridge, United Kingdom.
Entia Ltd is a medical technology company based in London, United Kingdom, that focuses on enhancing access to blood tests through innovative healthcare devices. Founded in 2014, Entia offers two primary products: Aptus, a device for testing haemoglobin and haematocrit levels, and Affinity, designed for cancer patients to monitor their blood counts from home. These devices facilitate health screening, blood donor screening, maternal and child health, nutrition, and sports applications, while also enabling cancer patients to manage their health more effectively, reducing the risk of infection and minimizing hospital visits. The company employs a multidisciplinary team that encompasses design, engineering, quality assurance, and business development, all aimed at improving patients' quality of life by allowing them to conduct essential health monitoring from the comfort of their homes.
Plasticell is a biotechnology company focused on developing innovative therapeutics through advanced cell culture and drug discovery platforms. The company specializes in elucidating the biochemical mechanisms that regulate the proliferation and differentiation of stem cells, which are essential for tissue development and repair. By testing a wide range of cell culture variables, Plasticell aims to establish optimal laboratory protocols for various applications in cell biology, gene transduction, protein production, and drug screening. This approach enables researchers to create novel small molecule drugs that promote regenerative medicine and improve therapeutic outcomes.
Small Pharma Ltd. is a pharmaceutical company founded in 2015 and headquartered in London, United Kingdom. The company specializes in developing a rapid-acting antidepressant aimed at treating patients with depression. Small Pharma employs a scalable model of outsourced drug development, utilizing expert teams to design and execute development programs. This approach leverages academic discoveries and focuses on effective intellectual property design, ensuring that the various disciplines essential for successful drug development are addressed by qualified professionals.
Elasmogen Ltd, a biopharmaceutical company, discovers and develops sight-saving therapies for inflammatory eye diseases. The company develops soloMER that are small (11 kDa) and stable proteins that have squeezed a fourth binding loop into their single domain format and are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape. Its pipeline includes ELN/21 and ELN/22, which are auto-immune mediated anti-inflammatory programs; soloMER-drug-conjugates; and NDure, a soloMER (humanized clinical candidate) available for extending the plasma half-life of fused partner molecules, such as scFv, peptides, growth factors, single domains, etc. Elasmogen Ltd has strategic partnerships with Almac Discovery Ltd and Merck Inc. The company was founded in 2014 and is based in Aberdeen, United Kingdom.
Autifony Therapeutics Limited is a biotechnology company based in London, United Kingdom, focused on developing innovative medicines for hearing disorders, including hearing loss and tinnitus. Established in 2011, the company leverages a drug discovery platform aimed at addressing unmet medical needs in this area. In addition to its primary focus on hearing-related conditions, Autifony's platform is also designed to alleviate symptoms associated with central nervous system disorders such as schizophrenia, fragile X syndrome, and Alzheimer's disease. By concentrating on these conditions, Autifony Therapeutics aims to provide effective treatment options for patients suffering from a range of debilitating disorders.
Arquer Diagnostics Ltd. specializes in the design, development, and commercialization of non-invasive immunoassay diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring small amounts of substances in body fluids, including a CE-marked ELISA kit for Mcm5, which is utilized in hospital pathology laboratories. Additionally, Arquer provides a point-of-care system that features a robust reader instrument and disposable cartridges, allowing for immediate testing in urology clinics, hospital laboratories, and general practitioners' surgeries. Founded in 2005 and formerly known as UroSens Ltd., the company is headquartered in Sunderland, United Kingdom, and is committed to improving cancer detection and monitoring to enhance patient outcomes.
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing and novel high value drugs with an unmet commercial or medical need .
N4’s commercial strategy is to advance a pipeline of products through clinical proof of concept and then partner to take the products through the relevant regulatory pathway studies to regulatory approval.
Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. The company offers a range of products, including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate's project, "Liver on chip," focuses on liver toxicity testing and incorporates advanced techniques in cellular reprogramming and organ-on-chip technology. The company also provides services such as cell reprogramming, differentiation, and application development. Its clientele includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions, enabling researchers to overcome challenges associated with traditional mammalian cell lines in drug discovery.
BrainWaveBank Limited is a brain health research company focused on developing innovative solutions to track and improve cognitive health, particularly in the context of dementia. Founded in 2015 and based in Belfast, United Kingdom, the company has created a unique wearable electroencephalography (EEG) device that allows users to non-invasively measure their brain activity. This device works in conjunction with mobile games designed to challenge cognitive skills, enabling individuals to monitor their cognitive health daily from the comfort of their homes. By securely collecting and analyzing data from a large user base, BrainWaveBank aims to build comprehensive neurocognitive profiles that can advance the understanding of brain health and inform the development of future treatments for neurological disorders. The company's approach emphasizes scalability and accessibility, making it a valuable tool for both consumers and clinical professionals.
LIFNano Therapeutics was founded in 2013 as a spin-out from the University of Cambridge, progressing to a clinical stage Nano-Bio-Med company specifically focused on targeted delivery of the biologic, Leukaemia Inhibitory Factor (LIF)..
CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.
Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.
Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal.
We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas.
This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide.
Having achieved proof of concept in humans, Renephra is raising £400k to conduct device development study and design feasability.
Sentinel Oncology Limited, a drug discovery company, develops and commercializes therapeutics to treat cancer. The company develops small molecule approaches to target the microenvironment of solid tumors. Its R&D programs pipeline includes Checkpoint Kinase 1, a protein kinase that activates in response to DNA damage and DNA replication stress; and an approach to treat metastatic breast cancer by developing a drug that inhibits S6K1 and offers treatment options for patients. The company was founded in 2005 and is based in Cambridge, United Kingdom.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.